stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Price to free cash flow
As of 6 November 2026, Travere Therapeutics, Inc. (TVTX) trades at a price to free cash flow of 55.3×. Over the past ten years it has ranged from 0.0× (June 2026) to 436× (August 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 25.2× and above the Healthcare sector median of 20.5×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 65.8× | (82.06%) |
| Jun 2026 | 367× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| DNTH Dianthus Therapeutics, Inc. compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| CRSP CRISPR Therapeutics AG compare | n/m |
| COGT Cogent Biosciences, Inc. compare | n/m |
| TVTX Travere Therapeutics, Inc. | 55.3× |
| Biotechnology industry median | 25.2× |
| Healthcare sector median | 20.5× |
| Market median | 14.0× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement